A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1,000 enrolled

Overview

Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Nasopharyngeal Carcinoma

Interventions

Epitope explorationDIAGNOSTIC_TEST

Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Controls underwent physical examinations or primary NPC cases confirmed by pathology or cytology. * If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th. * If cases, Karnofsky score (KFS)≥70, estimated survival span\>12 months. * If cases, no disordered of major organs is found; blood test, liver, and kidney functions are basically normal. * If cases, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Exclusion Criteria: * History of other malignant diseases. * History of severe systemic diseases or heart, lung, liver, or kidney disfunction. * History of severe neurological, metal, endocrine diseases. * History of HBV, HCV, HIV, TP, or TB infection. * If controls, physical examination reveals systemic diseases including malignant diseases. * If cases, incomplete blood and pathological sample data. * If cases, not receiving primary treatment in this facility. * Other individuals investigators find not suitable for the trial.

Outcomes

Primary Outcomes

Dominant gp42-IgG epitopes in cases

Dominant gp42-IgG epitopes revealed by ELISA with non-competitive monoclonal humanized antibodies against gp42 will be compared between cases and controls.

Time frame: Baseline